[144] UNITED THERAPEUTICS Corp SEC Filing

Rhea-AI Filing Summary

United Therapeutics (UTHR) Form 144 filing: This notice reports proposed and recent sales of the issuer's common stock by Martine Rothblatt. The filing shows a proposed sale of 4,000 shares through TD Securities on 09/23/2025 with an aggregate market value of $1,617,665.13. It discloses the securities were originally acquired on 03/15/2016 as executive deferred compensation and converted via vested options, totaling 294,000 shares acquired on that date. The filer also reported 44,000 shares sold across ten transactions from 09/09/2025 to 09/22/2025. The company had 45,230,000 shares outstanding per the form.

Positive

• Full disclosure of acquisition details including date (03/15/2016) and nature (executive deferred compensation)
• Broker and sale dates provided for proposed sale and prior trades, meeting Rule 144 disclosure requirements

Negative

• Significant insider selling reported: 44,000 shares sold from 09/09/2025 to 09/22/2025 and a proposed 4,000-share sale on 09/23/2025
• Potential perception risk from concentrated insider sales in a short period, which some investors may view negatively

Insights

Financial Analyst

TL;DR: Insider Martine Rothblatt disclosed recent and planned sales totaling 48,000 shares; amounts are disclosed and routine for executive-compensation conversions.

The filing details a proposed 4,000-share sale and prior monthly sales of 44,000 shares by a named insider. The shares were originally acquired as executive deferred compensation and converted via vested options, indicating these disposals stem from long-held compensation instruments rather than recent option grants. While the aggregate proceeds reported per trade are material in dollar terms, the share amounts represent a small fraction of the reported 45.23 million outstanding shares. For investors, this is transparent insider activity but not, by itself, an indicator of company financial stress or a corporate governance event.

Corporate Governance Expert

TL;DR: Disclosure is complete for Rule 144 purposes; frequent sales are notable but appear consistent with vesting/compensation mechanics.

The Form 144 provides required detail: number of shares, acquisition date (03/15/2016), nature of acquisition (executive deferred compensation), broker, and recent sale dates and proceeds. The filer attests to lack of undisclosed material adverse information. From a governance perspective, the filing meets procedural requirements and documents conversion and monetization of long-held compensation-related shares. Continued monitoring of insider selling cadence is reasonable, but this filing itself reflects routine disclosure compliance rather than a governance breach.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	TD SECURITIES (USA) LLC 125 PARK AVE, 20Th Floor New York NY 10017	4000	1617665.13	45230000	09/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/15/2016	Executive Deferred Compensation	Martine Rothblatt			294000	03/15/2016	Shares exercised via vested options and payment made via common shares

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/09/2025	8000	3188374.33
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/10/2025	4000	1594872.82
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/11/2025	4000	1588904.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/12/2025	4000	1615897.79
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/15/2025	4000	1591535.70
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/16/2025	4000	1601062.04
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/17/2025	4000	1600686.85
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/18/2025	4000	1617665.13
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/19/2025	4000	1644310.00
Martine Rothblatt 1000 Spring Street Silver Spring MD 20910	Common	09/22/2025	4000	1669212.50

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Martine Rothblatt disclose in the UTHR Form 144?

The filing discloses a proposed sale of 4,000 UTHR common shares on 09/23/2025, prior sales totaling 44,000 shares between 09/09/2025 and 09/22/2025, and that the shares were acquired on 03/15/2016 as executive deferred compensation.

How were the shares acquired according to the Form 144?

The shares were acquired on 03/15/2016 as executive deferred compensation and were converted via vested options with payment made using common shares.

What broker is handling the proposed sale listed in the filing?

The proposed sale of 4,000 shares is listed with TD Securities (USA) LLC, 125 Park Ave, New York and the intended exchange is NASDAQ.

How many UTHR shares were outstanding per the filing?

The Form 144 reports 45,230,000 shares outstanding.

Does the filing state whether the filer knows of any undisclosed material information?

Yes. The signer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.